Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Jun 16;9(12):e015656.
doi: 10.1161/JAHA.119.015656. Epub 2020 Jun 1.

Long-Term Association of Venous Thromboembolism With Frailty, Physical Functioning, and Quality of Life: The Atherosclerosis Risk in Communities Study

Affiliations
Comparative Study

Long-Term Association of Venous Thromboembolism With Frailty, Physical Functioning, and Quality of Life: The Atherosclerosis Risk in Communities Study

Pamela L Lutsey et al. J Am Heart Assoc. .

Abstract

Background Relatively little is known about the long-term consequences of venous thromboembolism (VTE) on physical functioning. We compared long-term frailty status, physical function, and quality of life among survivors of VTE with survivors of coronary heart disease (CHD) and stroke, and with those without these diseases. Methods and Results Cases of VTE, CHD, and stroke were continuously identified since ARIC (Atherosclerosis Risk in Communities Study) recruitment during 1987 to 1989. Functional measures were objectively captured at ARIC clinic visits 5 (2011-2013) and 6 (2016-2017); quality of life was self-reported. The 6161 participants at visit 5 were, on average, 75.7 (range, 66-90) years of age. By visit 5, 3.2% had had a VTE, 6.9% CHD, and 3.4% stroke. Compared with those without any of these conditions, VTE survivors were more likely to be frail (odds ratio [OR], 3.11; 95% CI, 1.80-5.36) and have low (<10) versus good scores on the Short Physical Performance Battery (OR, 3.59; 95% CI, 2.36-5.47). They also had slower gait speed, less endurance, and lower physical quality of life. VTE survivors were similar to coronary heart disease and stroke survivors on categorical frailty and outcomes on Short Physical Performance Battery assessment. When score on the Short Physical Performance Battery instrument was modeled continuously, VTE survivors performed better than stroke survivors but worse than CHD survivors. Conclusions VTE survivors had triple the odds of frailty and poorer physical function than those without the vascular diseases considered. Their function was somewhat worse than that of CHD survivors, but better than stroke survivors. These findings suggest that VTE patients may benefit from additional efforts to improve postevent physical functioning.

Keywords: frailty; physical function; quality of life; venous thromboembolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Linear regression of prevalent VTE events with gait speed and endurance in the Atherosclerosis Risk in Communities Study, 2011–2013 and 2016–2017.
A, Gait speed—4‐m walk (in meters per second). B, Endurance (in feet). CHD indicates coronary heart disease; and VTE, venous thromboembolism.
Figure 2
Figure 2. Polytomous logistic regression of prevalent VTE with Short Physical Performance Battery score and frailty in the Atherosclerosis Risk in Communities Study, 2011–2013.
A, SPPB score. B, Frailty. CHD indicates coronary heart disease; and VTE, venous thromboembolism.

Similar articles

Cited by

References

    1. Bell EJ, Lutsey PL, Basu S, Cushman M, Heckbert SR, Lloyd‐Jones DM, Folsom AR. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med. 2016;339.e19–26. - PMC - PubMed
    1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al. Heart disease and stroke statistics 2019 update: a report from the American Heart Association. Circulation. 2019;e56–e528. - PubMed
    1. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real‐world population: the Q‐VTE Study Cohort. Am J Med. 2013;832.e13–832.e21. - PubMed
    1. Lutsey PL, Horvath KJ, Fullam L, Moll S, Rooney MR, Cushman M, Zakai NA. Anticoagulant preferences and concerns among venous thromboembolism patients. Thromb Haemost. 2018;553–561. - PMC - PubMed
    1. Gaertner S, Cordeanu EM, Nouri S, Faller AM, Frantz AS, Mirea C, Bilbault P, Ohlmann P, Le Ray I, Stephan D. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): analysis of 6‐month outcomes. Int J Cardiol. 2017;103–109. - PubMed

Publication types

MeSH terms